Repositorio Dspace

Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study

Mostrar el registro sencillo del ítem

dc.contributor.author López-Manzanares, Lydia
dc.contributor.author Cerdán-Sánchez, María
dc.contributor.author Solano-Vila, Berta
dc.contributor.author Delgado-Ballestero, Tania
dc.contributor.author García-Ramos, Rocio
dc.contributor.author García-Caldentey, Juan
dc.contributor.author Rodríguez-Sanz, Ana
dc.contributor.author Olivares-Romero, Jesús
dc.contributor.author Gaston, Itziar
dc.contributor.author Carmona-Abellan, Mar
dc.contributor.author Mata-Álvarez-Santullano, Marina
dc.contributor.author Vázquez-Picon, Raquel
dc.contributor.author Rodríguez-de-Miguel, Marta
dc.contributor.author Tegel-Ayuela, Iciar
dc.contributor.author Magalhaes, Diogo
dc.contributor.author Holenz, Joerg
dc.date.accessioned 2026-11-11T09:05:27Z
dc.date.available 2026-11-11T09:05:27Z
dc.date.issued 2026-09-11
dc.identifier.citation López-Manzanares L, Cerdán Sánchez M, Solano Vila B, Delgado Ballestero T, García-Ramos R, García Caldentey J, et al. Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study. Brain Sci. 11 de septiembre de 2026;16(9):961. doi:10.3390/brainsci16090961
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29166
dc.description.abstract Objective: To evaluate the sustained real-world effectiveness and safety of catechol-O-methyltransferase (COMT) inhibitors added to levodopa in patients with Parkinson's disease (PD) presenting early motor fluctuations. Methods: REONPARK is an ongoing, multicenter, prospective observational study conducted in Spain. Adult patients with PD and end-of-dose motor fluctuations for <2 years initiating a COMT inhibitor were included. Outcomes assessed at 3, 6, and 12 months included Clinician and Patient Global Impression of Change (CGI-C, PGI-C), Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Wearing-off Questionnaire (WOQ-19), Non-Motor Symptoms Scale (NMSS), Parkinson's Disease Questionnaire-8 (PDQ-8), and safety. This article presents the 3-, 6-, and 12-month planned interim analysis of the study. Results: A total of 143 patients were included (99.3% treated with opicapone), of whom 138, 131, and 89 patients completed the 3, 6, and 12 months of follow-up, respectively. Levodopa doses remained stable in most patients (73% at 12 months). Significant and sustained improvements were observed in MDS-UPDRS Parts III and IV scores, as well as the total MDS-UPDRS score over 12 months, with greater likelihood of Part IV improvement in patients receiving <4.5 mg/kg/day of levodopa. OFF time decreased by 1.6-2.0 h from baseline. ON-time quality was maintained over time with 97.7% of patients reporting no or minimal functional impact from dyskinesia, while 47.7% of patients had no impact from motor fluctuations and 36.4% of patients no longer experienced OFF periods at 12 months. PDQ-8 scores remained stable and no overall benefit on total non-motor symptoms burden was demonstrated, despite improvements in selected domains among patients with a higher baseline non-motor symptoms burden. WOQ-19 scores improved significantly. Conclusions: In PD patients with early motor fluctuations, opicapone initiation was associated with sustained improvements in motor outcomes and reduced OFF time, and maintained the ON-time quality over 12 months, with stable levodopa dosing.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study
dc.type info:eu-repo/semantics/article
dc.relation.publisherversion https://www.mdpi.com/2076-3425/16/9/961
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.3390/brainsci16090961
dc.journal.title Brain Sciences
dc.identifier.essn 2076-3425


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta